Dr. Rahul Banerjee on the future of myeloma care

Oncology Insights: Dr. Petros Grivas sits down with Dr. Rahul Banerjee, a multiple myeloma specialist at Fred Hutch Cancer Center, to discuss how CAR T-cell therapy and bispecific antibodies are changing multiple myeloma care.

On this episode of Oncology Insights, host Petros Grivas, MD, PhD, FASCO, is joined by Rahul Banerjee, MD, FACP, a multiple myeloma specialist at Fred Hutch Cancer Center. They cover how CAR T-cell therapy and bispecific antibodies are changing myeloma care, ongoing Fred Hutch trials, working with community oncologists and the team approach behind it all.

Topics covered

Banerjee’s path to Fred Hutch and early exposure to CAR T-cell therapy.
CAR T-cell therapy in myeloma, including long-term CARTITUDE-1 outcomes and the evolving discussion around "cure."
CAR T-cell therapy toxicities, including CRS, neurotoxicity, infections and enterocolitis.
Bispecific antibodies, including MajesTEC-3 results and community-based delivery.
Choosing between CAR T-cell therapy and bispecific therapies.
Emerging frontline approaches, including antibody-based, steroid-sparing regimens.
Fred Hutch clinical trials, including dexamethasone-reduction studies and linvoseltamab dosing strategies.
Collaboration with community oncologists across the Pacific Northwest.
CAR T-cell therapy long-term follow-up and recognition of immune effector cell-associated enterocolitis.
CAR T-cell therapy for autoimmune diseases and lessons shared with oncology.
Multidisciplinary myeloma and amyloidosis care teams.
The future of myeloma treatment, including targeted therapies and antibody-drug conjugates.